Redcliffe Labs launches test for Mpox

Noida: Redcliffe Labs announced the launch of its advanced Mpox testing capabilities, the move is a step towards bolstering the nation’s preparedness against potential Mpox outbreaks.

Mpox, a highly contagious viral disease increasingly recognised for its potential to cause localised outbreaks, poses significant public health risks if not detected and controlled promptly. With several cases reported in Africa, Europe, and parts of Asia, the urgency of this threat necessitates early preparedness and timely intervention to prevent the virus from spreading.

The company has proactively assured key health authorities, including Noida's Chief Medical Officer (CMO) and the Indian Council of Medical Research (ICMR), of its readiness to manage the Mpox situation. Being prepared with advanced testing facilities not only ensures the rapid identification and isolation of cases but also guarantees that healthcare providers are fully equipped to handle increased demand. Additionally, it enables timely public communication and education, reducing misinformation and helping manage the community impact.

Aditya Kandoi, CEO, Redcliffe Labs, said, “We are ready to work closely with health authorities to ensure the safety and well-being of our community."

"Mpox, similar to other highly contagious viral infections, demands early detection for timely and effective intervention. Early diagnosis is crucial to preventing complications, limiting the spread of the disease, and safeguarding public health. By ensuring swift identification, we can enhance patient outcomes and protect communities from further outbreaks," said Dr Geetanjali Gupta, Director-Technical Operations and Quality Assurance, Redcliffe Labs.

The company aims to enhance national pandemic defence and safeguard public health against Mpox threats through strategic readiness and innovative diagnostic solutions.